The QualityStocks Daily Tuesday, July 24th, 2018

Today's Top 3 StockMarketWatch

OTCtipReporter (SCON) +660.64%

TopPennyStockMovers (NBGV) +46.67%

NetworkNewsWire (ASCK) +45.53%

The QualityStocks Daily Stock List

Bespoke Extracts, Inc. (BSPK)

YCharts, Morningstar, Market Exclusive, Ventureline, Stockopedia, Investors Hangout, Wallet Investor, Infront Analytics, Simply Wall St, Stockhouse, Marketwired, MarketWatch, and Wallmine reported on Bespoke Extracts, Inc. (BSPK), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Bespoke Extracts, Inc. is a producer of high quality, flavorful, hemp-derived cannabidiol (CBD) extract products. The Company formed in early 2017 to introduce a proprietary line of premium quality, all-natural CBD products in the form of tinctures and capsules for the nutraceutical and veterinary markets. Bespoke Extracts has its corporate office in Sunny Isles Beach, Florida.

Today, Bespoke Extracts announced that its common stock was approved for up-listing to the OTCQB Venture Market Place, effective immediately. The OTCQB is a venture market. The design of this market is for early-stage and developing U.S. and international companies.

The Company’s products are produced using pure, all natural, zero-THC phytocannabinoid-rich (PCR) hemp-derived CBD. CBD is non-psychoactive.

Bespoke’s products are marketed as dietary supplements and distributed by way of the Company’s direct-to-consumers ecommerce store. Bespoke Extracts strives to use only vegan, Fair Trade Certified, and organic ingredients with fast acting benefits for anyone looking for an alternative remedy.

Bespoke Extracts’ emphasis is on premium ingredients. The Company’s farmers have been innovators in hemp agriculture, farming practices, agrotech, as well as production for generations. Bespoke’s hemp is stable, high in CBD, low in THC, and resistant to pests and pathogens.

The Company’s products include Sport Lemon Lime Tincture – THC Free 1500MG; CBD Manuka Honey Tincture; and CBD Bacon Flavored Pet Tincture. Products also include CBD Softgel Capsules; CBD Pain Relief Cream; and CBD Isolate Powder.

Earlier this month, Bespoke Extracts announced that it signed an agreement with Seidman Food Brokerage (SFB), providing for SFB to market Bespoke Extract’s proprietary CBD tinctures, lotions, and salves to over 1,500 stores located in Alabama, Florida, Georgia, North Carolina, South Carolina, Tennessee, The Bahamas and Puerto Rico.

Mr. Marc Yahr, President and Chief Executive Officer of Bespoke Extracts, said, “Our agreement with Seidman Food Brokerage marks a key inflection point in our go-to-market strategy and sets the stage for our achieving dynamic new revenue growth in our retail channel on a moving forward basis.  Given that Seidman is one of the industry’s most respected food brokerage firms, we take great pride in their decision to market Bespoke CBD products to their valued retail clients.”

Bespoke Extracts, Inc. (BSPK), closed Tuesday's trading session at $1.26, up 3.28%, on 20,193 volume with 21 trades. The average volume for the last 60 days is 1,367 and the stock's 52-week low/high is $0.105/$3.00.


OP Bancorp (OPBK)

The Street, Businesswire, TradingView, MarketWatch, and YCharts reported on OP Bancorp (OPBK), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A California corporation, OP Bancorp is the holding company for Open Bank. Open Bank engages in the general commercial banking business in Los Angeles and Orange Counties, California. The Bank concentrates on serving the banking needs of small- and medium-sized businesses, professionals, and residents with a specific focus on Korean and other ethnic minority communities.

The Company began its operations on June 10, 2005 as First Standard Bank. It changed its corporate name to Open Bank in October of 2010. OP Bancorp lists on the OTCQB and the Company is headquartered in Los Angeles.

At present, the Bank operates with seven full branch offices in Downtown Los Angeles, the Los Angeles Fashion District, Los Angeles Koreatown, Gardena and Buena Park. In addition, it has three loan production offices in Seattle, Washington; Dallas, Texas; as well as Duluth, Georgia.

Open Bank generates certificates of deposit, instalment accounts, money market accounts, retirement accounts, savings accounts, and various personal and business checking accounts. Additionally, it provides commercial lending products, such as business lines of credit, business term loans, and commercial real estate term loans; trade financing products and services consisting of issuance of letters of credit, import and export financing, revolving lines of credit, clean and documentary collections, and others.

Moreover, Open Bank offers small business administration lending products and home mortgage financial solutions. It also offers online banking, mobile banking, bill pay, and e-statement services. Open Bank’s vision and mission is to be known as a faith-based community bank centered on relationship banking.

This past July, OP Bancorp reported that Net Income for Q2 of 2017 was $2.46 million, or $0.18 per diluted common share. This is in comparison to Net Income of $2.15 million, or $0.15 per diluted share, for Q1 of 2017, and Net Income of $1.80 million, or $0.13 per diluted share, for Q2 of 2016.

Pre-Tax Pre-Provision Income was $4.3 million for Q2 2017, versus $4.1 million for Q1 2017, and $3.5 million for Q2 2016.

OP Bancorp (OPBK), closed Tuesday's trading session at $12.85, down 0.54%, on 26,700 volume. The average volume for the last 60 days is 69,368 and the stock's 52-week low/high is $7.90/$14.10.


Diego Pellicer Worldwide, Inc. (DPWW)

MarketWatch reported on Diego Pellicer Worldwide, Inc. (DPWW), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Diego Pellicer Worldwide, Inc. is a real estate and consumer retail development company. It concentrates on developing the Company as the world’s first "premium" marijuana brand. The Company’s tenants are stand-alone, independent businesses and Diego Pellicer Worldwide has no ownership in them. Via the development and acquisition of premium, legally compliant real estate locations for cannabis growers and retailers, Diego Pellicer provides a best-in-class platform for new business growth in the cannabis industry. Diego Pellicer Worldwide is based in Seattle, Washington and the Company’s shares trade on the OTC Markets’ OTCQB.

Diego Pellicer does not grow or sell marijuana or marijuana infused products. The Company leases legally compliant locations for growing, retailing, or the medical dispensing of marijuana.

The Company’s initial focus is to acquire and develop legally compliant real estate locations for the purposes of leasing them to State licensed companies in the cannabis industry. Its initial revenues originate from leasing real estate and selling non-cannabis related products.

However, when it is federally legal to do so, Diego Pellicer said it will be properly positioned to take advantage of pre-negotiated acquisition contracts with selected Diego Pellicer tenants in marijuana retail and production facilities throughout the country.

In addition, Diego Pellicer participates in the profit of café operations of non-infused products; participates in the profit of ancillary products, including branded apparel; and in some instances, it signs contracts with its tenants, with the right to acquire at its discretion. It has secured numerous first-rate locations in Colorado, Washington, and Oregon. The Company is an international brand by Diego Pellicer Worldwide.

Diego Pellicer Worldwide has leased two facilities to grow operators in Denver, Colorado. These grow facilities are licensed for medical and recreational cannabis. The facilities are greater than 30,000 sq. ft.

Its first flagship store tenant, Diego Pellicer Washington (3,000 sq. ft. space) passed its final inspection for retail marijuana sales and began operations in Q4 of 2016. This flagship store features high-end cannabis product and accessories.
Diego Pellicer Worldwide and branded tenant Diego Pellicer Washington announced in September of 2016 opening Seattle's first quality cannabis store. The luxury marijuana store opened on October 7, 2016.

In February 2017, Diego Pellicer announced the grand opening of its Denver, Colorado-based dispensary tenant, Diego Pellicer - Colorado, on February 14, 2017. The $1 million dispensary will provide thousands of Denver residents with access to cannabis in an upscale, high-end location.

In essence, Diego Pellicer is where responsible marijuana connoisseurs and sommeliers convene to explore the world of premium marijuana. The Company is the global leader in property acquisitions and leasing in the developing cannabis space.

Diego Pellicer Worldwide, Inc. (DPWW), closed Tuesday's trading session at $0.0081, up 14.08%, on 2,384,937 volume with 47 trades. The average volume for the last 60 days is 1,743,482 and the stock's 52-week low/high is $0.007/$0.19.


International Stem Cell Corp. (ISCO)

MissionIR, Tiny Gems,, StocksToBuyNow,, and Serious Traders reported earlier on International Stem Cell Corp. (ISCO), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, International Stem Cell Corp. is a clinical stage biotechnology enterprise. The Company is developing stem cell-based therapies and biomedical products. Its concentration is on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The Company’s core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs).

The hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. They offer the potential to create the first true stem cell bank, UniStemCell™. International Stem Cell has its corporate office in Carlsbad, California. It has a research facility in Oceanside, California.

International Stem Cell scientists have created the first parthenogenetic, homozygous stem cell line. This line can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages, and racial backgrounds with minimal immune rejection post transplantation. A relatively small number of hpSC lines could provide enough immune-matched cells to cover a large percentage of the world’s population.

The Company produces and markets specialized cells and growth media for therapeutic research internationally through its subsidiary Lifeline Cell Technology (Frederick, Maryland) and stem cell-based skin care products by way of its subsidiary Lifeline Skin Care.

International Stem Cell has demonstrated that ISC-hpNSC® can improve cognitive performance and motor coordination in rodents with traumatic brain injury. Also, ten pending patent applications covering internally-generated and in-licensed technologies have been issued as patents.

The Company’s subsidiary, Lifeline Skin Care, has expanded its two core technology product lines through launching four new skincare products targeting retail and professional markets. In 2016, a new patent covering small molecule technology in skin care was issued to International Stem Cell in the United States

Concerning the UniStemCell™ bank, it is the life science industry’s first collection of non-embryonic histocompatible human stem cells available for research and commercial use. The human leukocyte antigen (HLA) system represents antigens important for transplantation.

Last week, International Stem Cell reported that two more patients with Parkinson’s disease were successfully transplanted with the Company’s proprietary ISC-hpNSC® cells at the Royal Melbourne Hospital (RMH), in July and August, 2017. The two patients are part of the second cohort clinical trial being treated for Parkinson’s disease.

The two patients received a moderate dosage of ISC-hpNSC® cells using CT- and MRI-guided stereotactic brain surgery. The operations were successfully performed by the team of RMH neurosurgeons without complications. This Phase I clinical study is a dose escalation safety and preliminary efficacy study of ISC-hpNSC®, intracranially transplanted into patients with moderate to severe Parkinson's disease.

International Stem Cell Corp. (ISCO), closed Tuesday's trading session at $1.53, up 1.32%, on 1,720 volume with 10 trades. The average volume for the last 60 days is 8,992 and the stock's 52-week low/high is $1.08/$2.05.


Synergy CHC Corp. (SNYR)

SmallCapVoice, MarketWatch, OTC Markets, and TradingView reported earlier on Synergy CHC Corp. (SNYR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Synergy CHC Corp. is a consumer health care company listed on the OTC Markets. It is in the process of building a portfolio of best-in-class consumer product brands. The Company’s strategy is to increase its portfolio organically and through further acquisition. Established in 2012, Synergy CHC is headquartered in Westbrook, Maine.

The Company sells its products mainly in North American retail locations. Its diversified portfolio includes Flat Tummy Tea™, FOCUSFactor™, Neuragen™, and Hand MD®. Flat Tummy Tea™ is an innovatively formulated two-step herbal detox tea. It works to naturally help speed up metabolism, boost energy, and reduce bloating to flatten one’s stomach/tummy.

FOCUSFactor is a nutritional supplement. It includes a proprietary blend of brain supporting vitamins, minerals, antioxidants, and other nutrients.

Neuragen® is a topical product. It works directly at the site of the pain contrasted with oral products. Neuragen® reduces the spontaneous firing of damaged peripheral nerves.

Also, Synergy CHC’s Hand MD® is the world's first anti-aging skincare line formulated specifically for the hands. Synergy CHC has also launched its newest brand, Sneaky Vaunt®.

Synergy CHC officially launched The Synergy Effect, its ROI (Return on Investment) innovation engine and online marketing platform. The Synergy Effect was built to boost online revenue growth for all of the Company’s brands.

This past June, Synergy CHC announced that it entered into, and at the same time closed on, an Asset Purchase Agreement with Per-fekt Beauty Holdings, LLC and CDG Holdings, LLC, which owns 92.3 percent of the issued and outstanding equity interests of Per-fekt Beauty. Per-fekt Beauty engages in developing and selling skincare and cosmetics products under the brand Per-fekt.

With this Purchase Agreement, Synergy CHC purchased all of Per-fekt Beauty's assets and assumed certain of its liabilities for a purchase price of $709,988.34. As additional consideration, it will pay quarterly royalties equal to 5 percent of Net Sales for 10 years following the closing date.

Last month, Synergy CHC reported results for the quarter ended June 30, 2017.

Net Sales were $9.3 million, versus $8.2 million for the same quarter in 2016. This represents a 13 percent increase. For Q2, Net Loss was $0.05 million or $0.00 (basic and diluted) earnings per share, versus a Net Loss of $0.01 million or $0.00 (basic and diluted) earnings per share for 2016.

Net Sales for the six months ended June 30, 2017 were $20.1 million, versus $16.5 million for the same period in 2016. This represents a 22 percent increase. For the six months ended June 30, 2017, Net Income was $2.5 million, or $0.03 (basic and diluted) earnings per share, versus Net Income of $2.8 million or $0.03 (basic and diluted) earnings per share for the same period in 2016.

During the six months of 2017, the Company reduced its debt to $3.6 million from $7.6 million. This represents a 53 percent decrease.

Synergy CHC Corp. (SNYR), closed Tuesday's trading session at $0.30, up 15.38%, on 200 volume with 2 trades. The average volume for the last 60 days is 7,737 and the stock's 52-week low/high is $0.26/$0.5921.


Biostage, Inc. (BSTG)

StockNewsJournal, Simply Wall St, BusinessInsider, Barchart, The Street, StockTwits, Investors Hub, Stock News Gazette, Zacks, InvestorPoint, and AllStockNews reported on Biostage, Inc. (BSTG), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Biostage, Inc. is a biotechnology enterprise whose shares trade on the OTC Markets’ OTCQB. The Company is developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea. Biostage previously went by the name Harvard Apparatus Regenerative Technology, Inc. It changed its name to Biostage, Inc. in March of 2016. Biostage has its corporate headquarters in Holliston, Massachusetts.

The Company is developing bioengineered organ implants based on its Cellframe™ technology. This technology combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants.

Based on its preclinical data, Biostage has selected life-threatening conditions of the esophagus as the initial clinical application of its technology. Cellspan implants are undergoing development to treat life-threatening conditions of the esophagus, bronchus or trachea with the hope of significantly improving the treatment model for patients.

The basis of Biostage’s Cellframe technology is on greater than 20 years of scientific progress in the fields of tissue engineering, cell biology, and material science. Cellframe technology combines the best attributes of a synthetic scaffold with tissue engineering and cell biology. The Company’s novel Cellframe™ technology is engineered to stimulate the body’s signaling pathways and natural healing process to regenerate and restore organ function.

At the end of May, Biostage announced that it elected Mr. Hong Yu as President, effective May 29, 2018. Mr. Yu brings considerable experience in cross-border business development to Biostage. He is an experienced executive with wide-ranging knowledge in strategic analytics, wealth management, and investment research. Before Biostage, Mr. Yu was most recently a Senior Vice President responsible for strategic analytics at Bank of America.

Mr. Yu will report to Chief Executive Officer Mr. Jim McGorry. Mr. Yu will be responsible for raising capital to advance the Company’s Cellframe™ technology from pre-clinical studies to clinical trials, in addition to leading development for China expansion.

Biostage, Inc. (BSTG), closed Tuesday's trading session at $3.85, down 1.28%, on 859 volume with 10 trades. The average volume for the last 60 days is 3,746 and the stock's 52-week low/high is $0.60/$13.00.


Giggles N' Hugs, Inc. (GIGL)

SeriousTraders,, RedChip, OTCJournal, StocksToBuyNow, SmallCap Network, Investor's Insight, RedChip, SmallCapVoice, and Money and Markets reported on Giggles N' Hugs, Inc. (GIGL), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Giggles N' Hugs, Inc. is the owner and operator of family-friendly restaurants. These restaurants bring together high-end, organic food with active, leading-edge play and entertainment for children. The Company features high-quality menus made from fresh and local foods. Established in 2010, Giggles N' Hugs is headquartered in Los Angeles, California.

Each Giggles N' Hugs location offers an upscale, family-friendly atmosphere with a dedicated play area for children 10 and younger. Additionally, the Company features nightly entertainment. This includes magic shows, concerts, puppet shows, and face painting, and party packages for families.

Membership at Giggles N' Hugs comes with benefits. These include first access to its special kids’ events, monthly deals, and unlimited visits for the whole family. The Company was voted the #1 birthday party place in Los Angeles by Nickelodeon. Moreover, it was voted "Best Pizza in Los Angeles" by Nickelodeon.

Giggles N' Hugs was also listed best family & kid-friendly restaurants by CitySearch and GoCityKids. The Company has locations in Century City, Topanga, and Glendale, California.

Giggles N’ Hugs has engaged PacificShore Ventures to explore potential synergistic acquisition opportunities. PacificShore is an international specialty finance and Mergers & Acquisitions (M&A) firm.

Giggles N' Hugs is targeting companies, which are cash flow positive and have minimum annual revenue of $5 million or more. PacificShore will work to identify and create target company profiles, introduce, initiate negotiations, and ultimately facilitate the closing of such potential companies and introduce traditional banking relationships for Giggles N' Hugs to finance the acquisitions.

Giggles N’ Hugs announced in May 2017 that it signed a non-binding Letter of Intent (LOI) with City Scape trading (franchisee), a Bahrain-based hospitality company, to open up to two Giggles N’ Hugs franchise locations in Bahrain with additional locations to come if successful. With this master license agreement, Giggles N’ Hugs will receive up-front development fees for each location, and also an ongoing royalty based on a percentage of monthly gross sales.

Giggles N’ Hugs announced in June that its Global Brand Ambassador, Jillian Michaels, would launch Fitness Friday programs and introduce healthy new menu items for the Company’s locations. Jillian Michaels is a world-renowned wellness expert, business entrepreneur, and mom.

Recently, Giggles N’ Hugs announced its financial performance for Q2 ended July 2, 2017. Q2 highlights include same store Net Sales for its Glendale location increasing 4.3 percent year-over-year. Same store Net Sales for its Topanga location increased 5.0 percent year-over-year.

The Company’s Cost of Operations decreased 41.5 percent year-over-year to $429,164. Its Loss from Operations improved 46.2 percent year-over-year. The Glendale location produced record positive cash flow of more than 35 percent at the unit level.

Giggles N' Hugs, Inc. (GIGL), closed Tuesday's trading session at $0.010125, up 6.58%, on 1,124,350 volume with 26 trades. The average volume for the last 60 days is 272,036 and the stock's 52-week low/high is $0.0084/$0.091.


CVR Medical Corp. (CRRVF)

OTC Markets and MarketWatch reported on CVR Medical Corp. (CRRVF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

CVR Medical Corp. is engaged in an equal part joint venture (JV) with CVR Global, Inc. The JV operates in the medical industry centered on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology. A medical technology enterprise, CVR Medical is headquartered in Vancouver, British Columbia and the Company’s shares trade on the OTC Markets Group’s OTCQB.

The JV has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. The Carotid Stenotic Scan (CSS) is a unique tool that will be used to assess Carotid Arterial health in a way that is unavailable to the patient, healthcare provider, and the payor within the present system.

The CSS is a screening tool designed to detect and measure carotid arterial stenosis or occlusion for the purpose of identifying patients at risk for Ischemic Stroke. The CSS provides a synergistic tool that complements other stroke screening technology. The screening device is non-emissive and non-invasive. It does not require a certified technician and can be conducted in a few minutes.

The CSS has a per scan price point that is significantly advantageous as an initial screening tool versus the resource requirement associated with other technologies. CVR’s technology makes a connection between fluid flow and sub-sonic frequencies to ascertain the presence of arterial disease/blockage.

CVR Medical is entering the Clinical phase of the development process. The final market version of the CSS is undergoing assembly and preparation for Pivotal Trials, which will then undergo submission for Food and Drug Administration (FDA) 510(k) clearance.

CVR Medical reported in March of this year that it entered into a letter of intent (LOI) with CVR Global, Inc. to acquire an additional 10 percent interest of the "Joint Venture Business" from CVR Global's present 50 percent interest. The Joint Venture Business is held pursuant to, and governed by, the terms of the Joint Venture Agreement between CVR Global and CVR Medical.

Upon the closing of the Transaction, the Joint Venture Business and related assets will be transferred into a new corporate entity to be created for the continuing ownership and operation of the business.

Furthermore, in March, CVR Medical announced a partnership with ADCO Circuits. ADCO will be the exclusive provider of the custom circuit board inside the sensor of CVR Medical's Carotid Stenotic Scan (CSS) device. ADCO Circuits is a Michigan-based electronic design and manufacturing enterprise.

In April, CVR Medical announced an update on clinical trials of the Carotid Stenotic Scan (CSS), being conducted by way of the Jefferson Clinical Research Institute at Thomas Jefferson University under the supervision of Dr. David J. Whellan.

Dr. Whellan said, "Enrollment was initiated in early January. The prototype device, which is being operated in standard form, will soon be joined by its wireless charging technology, for which preparation has gone smoothly. The CSS, as a whole, has been widely praised for its ease of use. The training required was straightforward and allowed the coordinators to quickly gain experience and implement the study. Since its successful implementation, we have had steadily growing enrollment. We're looking forward to continuing our work with CVR."

Last week, CVR Medical advisory staff member Dr. Phillip J. Bendick, PhD, released a summarized report on data from the tertiary clinical trials for the Carotid Stenotic Scan (CSS) device at Thomas Jefferson University. His report views initial evaluations as successful, and confirms the device's value and efficiency.

This week, CVR Medical announced that an institutional research report was released by RB Milestone Group, LLC (RBMG). This report on CVR Medical titled "Revolutionizing the Vascular Diagnostics Market" can be found on the website at or by contacting Trevor Brucato, Managing Director at RBMG. RB Milestone Group is a New York based consulting firm that CVR Medical engaged to provide the report.

CVR Medical Corp. (CRRVF), closed Tuesday's trading session at $0.28, up 2.83%, on 16,806 volume with 15 trades. The average volume for the last 60 days is 36,304 and the stock's 52-week low/high is $0.221/$0.4159.


CurAegis Technologies, Inc. (CRGS)

Equity Clock, 4-Traders, InvestorsHub, Simply Wall St, and OTC Markets reported on CurAegis Technologies, Inc. (CRGS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

CurAegis Technologies, Inc. develops and markets advanced technologies in the areas of power, safety, and wellness. The Company consists of two independent divisions. One is its CURA Division and the other is its Aegis Division. CurAegis is currently focusing on commercialization strategies in varied technologies. These include the CURA system, which includes the myCadian™ watch that measures degradation of alertness and sleep attributes; the Z-Coach e-learning education and training tool, and the Aegis hydraulic pump.

CurAegis Technologies is headquartered in Rochester, New York. The Company lists on the OTC Markets Group’s OTCQB.

The CURA™ system and the myCadian™ watch enable the user and third parties to anticipate and prevent undesired or disastrous situations caused by the degradation of alertness. The Company completed its validation studies of the CURA System at the University of Colorado at Boulder and the University of Rochester Medical Center. It previously said that it can now state that it can predict a person’s fatigue level, at close to laboratory accuracy, in real-time.

The CURA System consists of hardware and software that measures manifold metrics to establish that a person's ability to perform a task or job appears to be degrading. The CURA division is developing a proprietary technology and family of products designed to measure the reduction in a person’s alertness and to train persons on how to improve alertness levels. The CURA System gives a person accurate and relevant real-time information concerning their present and long-term sleep and fatigue health.

CurAegis Technologies’ Aegis hydraulic pump (Aegis Division) is a unique hydraulic design. Its objective is to deliver better efficiencies in a package that is smaller and lighter than contemporary technologies.

The Z-Coach e-learning tool was acquired by CurAegis Technologies in September 2015. The first of six Z-Coach e-learning modules, Z-Coach Aviation, was designed for aviation professionals. If the CURA (Circadian User Risk Assessment) software detects an issue, Z-Coach creates a back-end solution needed to induce change and improve behavior. This program is broken down into two parts: Z-Coach Education and Z-Coach Intervention.

CurAegis Technologies’ plan is to license its technology to major manufacturers. The Company may consider an exclusive licensing agreement for a period of time if it believes that it is the best way to reach original equipment manufacturer (OEM) and after-market customers.

In May, CurAegis Technologies reported that it launched its CURA System designed for use with the FITBIT® Platform. The Company noted that its internal testing has been very positive. CurAegis has sold and shipped product. The Company is preparing to commence major pilots.

In addition, CurAegis has launched its business to business (B2B) sales programs. The Company stated that users will be able to purchase the FITBIT® via a link on its website or use their existing FITBIT®. CurAegis expects to introduce applications for the myCadian® and other watches for use with the CURA System in the near future.

CurAegis Technologies, Inc. (CRGS), closed Tuesday's trading session at $0.3099, down 6.80%, on 30,264 volume with 11 trades. The average volume for the last 60 days is 34,716 and the stock's 52-week low/high is $0.20/$0.76.


MGT Capital Investments, Inc. (MGTI)

TipRanks, Zacks, Insider Tracking, Stockhouse, Simply Wall St, Insider Financial, Finance Registrar, OTC Markets, Barchart, Equity Clock, and InvestorsHub reported on MGT Capital Investments, Inc. (MGTI), and we also report on the Company, here at the QualityStocks Daily Newsletter.

MGT Capital Investments, Inc. ranks as one of the largest U.S.-based Bitcoin miners. The Company has its facility in Washington State. In addition, it has a facility in northern Sweden. Moreover, MGT continues to focus on an expansion model to secure low cost power as well as grow its crypto assets materially.

MGT Capital Investments’ shares trade on the OTC Markets Group’s OTCQB. The Company has its head office in Durham, North Carolina.

MGT owns and operates roughly 6,800 Bitmain S9 miners, and 50 GPU-based Ethereum mining rigs. The Company signed a Letter of Intent (LOI) with Bitmain Technologies Limited. This is to establish a JV that will concentrate on opportunities in the Bitcoin space in North America. The proposed JV between MGT Capital Investments and Bitmain Technologies will lead to the development of a state-of-the-art Bitcoin mining pool.

MGT has also entered into a consulting agreement with Future Tense Secure Systems, Inc. Future Tense is a technology incubator with investments in other applications requiring privacy, such as chat and file sharing.

MGT Capital Investments began Bitcoin Mining in September 2016 in Washington State. These facilities are still presently mining. In Q1 of 2018, MGT began a transition of its mining assets from Washington State to Northern Sweden.

Last week,  MGT Capital Investments announced the appointment of Mr. Stephen Schaeffer as Chief Operating Officer (COO) of the Company. Since August 2017, Mr. Schaeffer has served as President of MGT’s Crypto-Capital Strategies division.

In this role, Mr. Schaeffer has led the Company's crypto team domestically and also the expanded operation in Sweden. Since 2012, Mr. Schaeffer has a wide-ranging background in building and operating large scale crypto mining centers. He also has strong relationships with some of the largest hardware manufacturers and many of the most influential individuals in the Bitcoin industry.

MGT Capital Investments, Inc. (MGTI), closed Tuesday's trading session at $1.00, up 9.90%, on 1,985,603 volume with 1,075 trades. The average volume for the last 60 days is 645,801 and the stock's 52-week low/high is $0.68/$8.14.


Avalon Globocare Corp. (AVCO)

NetworkNewsWire, OTC Markets, Information Vine, Dynamic Wealth Research, Business Insider, Wallet Investor, Whale Wisdom, InvestorsHub, and TradingView reported on Avalon Globocare Corp. (AVCO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Avalon Globocare Corp. provides healthcare services in the U.S. and China. The Company operates via its main platforms: Avalon Cell and Avalon Rehabilitation. Avalon Globocare is a premier healthcare management provider and biotechnology developer. Its commitment is to integrate and manage worldwide healthcare resources. Avalon Globocare has its headquarters in Freehold, New Jersey.

In addition, the Company, through its subsidiary “Avalon RT9 Properties, LLC”, engages in the acquirement and management of healthcare facilities. Regarding Avalon Globocare’s healthcare facility, it currently includes healthcare property management services, chiefly through acquiring and managing healthcare real estate facilities, stem cell banks, and a CAP-certified laboratory, which will complement the Company’s existing platforms.

The “Avalon Rehabilitation” platform is a turnkey, complete set of rehabilitation services. These services include PT, OT, robotic engineering, cybernectics, and clinical nutrition. The Company’s “Avalon Cell” platform focuses on cell-based therapies and technologies. Its concentration is in the field of in vitro diagnostics, regenerative medicine, and cancer immunotherapy.

Avalon Cell focuses on transformative and high-impact cell-based bio-technology opportunities in the U.S. and China. It then fast tracks these to clinical development and commercialization globally.

Avalon Globocare’s majority-owned subsidiary, GenExosome Technologies, Inc., has acquired 100 percent of the outstanding capital stock of Beijing Jieteng (Beijing GenExosome) Biotech Co. Ltd.  GenExosome also entered into and closed an Asset Purchase Agreement with Dr. Yu Zhou, Chief Executive Officer of GenExosome Beijing, where GenExosome acquired all assets, including all intellectual property (IP), patents and patent applications held by Dr. Zhou regarding the business of researching, developing, and commercializing exosome technologies.

Recently, Avalon Globocare announced that it created a joint venture (JV) with Jiangsu Unicorn Biological Technology Co. Ltd. that brings wide-ranging medical resources in Jiangsu Province, China. The partnership was created to lead to the development of a first-class network of provincial centers of excellence for translational research, collaborating in the areas of technological, clinical and regulatory resources in the areas of cellular therapy and bio-banking from leading hospitals.

Last week, Avalon Globocare announced that it established a new wholly-owned U.S. subsidiary, Avactis Biosciences, Inc. This subsidiary will center on fast-tracking commercial activities related to its proprietary Chimeric Antigen Receptor (CAR)-T technologies.

The design of Avactis Biosciences is to integrate and optimize Avalon’s worldwide scientific and clinical resources.  CAR-T is a novel and ground-breaking cancer immunotherapy. It involves genetically modifying T cells to activate the immune system to recognize and destroy cancer cells.

Avalon Globocare Corp. (AVCO), closed Tuesday's trading session at $2.90, up 2.84%, on 1,500 volume with 2 trades. The average volume for the last 60 days is 3,420 and the stock's 52-week low/high is $0.51/$4.60.


Indoor Harvest Corp. (INQD)

Orbit Stocks, CFN Media Group, Cannabis Financial Network News, MassiveStockProfits, SmallCapVoice, Fast Money Alerts, Stock Shock and Awe, OTPicks, Penny Stock General, and PennyPickAlerts reported earlier on Indoor Harvest Corp. (INQD), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Indoor Harvest Corp. is a developer of personalized cannabis medicines. The Company is also a provider of advanced cultivation technology, methods, and processes. Indoor Harvest provides the cannabis industry production platforms for Building Integrated Agriculture (BIA) production. OTCQB-listed, Indoor Harvest has its corporate office in Houston, Texas.

The Company entered into an Agreement and Plan of Merger with Alamo CBD, on August 4, 2017. Indoor Harvest has transitioned into a producer of cannabis for research and pharmaceutical development. Its patent pending aeroponic methods allow for the production of chemically consistent, contaminate free cannabis, economically at scale.

Indoor Harvest is a pending applicant under the Texas Compassionate Use Program. Its plan is to develop facilities in Arizona and Colorado. The Company is looking to use the relationships and technology it has developed to become a registered producer and seller under the federal Controlled Substance Act (CSA) of pharmaceutical grade Cannabis for research by third parties developing targeted treatment for specific medical symptoms.

Currently, Indoor Harvest is a pending applicant through its acquisition of Alamo CBD, to produce cannabis, under the Texas Compassionate Use program. The Company’s plan is to produce revenue from its developed facilities through leasing and licensing of its technology and methods.

In October 2017, Indoor Harvest and Zoned Properties, Inc. announced that the two companies entered into a Binding Letter of Intent (LOI) outlining three independent agreements to complete research and development (R&D) projects for licensed medical marijuana facilities to be located in Tempe, Arizona; Parachute, Colorado; and Stockdale, Texas, or other location to be determined after approval of a provisional license under the Texas Compassionate Use program. Zoned Properties is a strategic real estate development company.

Indoor Harvest’s financial results for the quarter ended March 31, 2018, versus the quarter ended March 31, 2017, include an 88 percent reduction in Net Loss from $1,056,253 to $127,216. Financial results also include a 62 percent reduction in Total Operating Expenses from $726,828 to $272,603.

During Q1 2018, Indoor Harvest completed initial conceptual design and engineering work to integrate its HPA technology with HVAC systems with its partner Harvest Air, LLC. In addition, the Company entered into discussions with cannabis producers in the U.S. and Canada to use its technology and methods.

Indoor Harvest Corp. (INQD), closed Tuesday's trading session at $0.09, up 6.45%, on 87,269 volume with 18 trades. The average volume for the last 60 days is 69,929 and the stock's 52-week low/high is $0.0501/$0.45.


Acorn Energy, Inc. (ACFN)

MegaPennyStocks, Catalyst IR, Wall Street Resources, Wealthpire, SmarTrend Newsletters, Marketbeat, and Hit and Run Candle Sticks reported on Acorn Energy, Inc. (ACFN), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Acorn Energy, Inc. is a provider of machine-to-machine, Internet of Things (IoT) remote monitoring and control systems and services. Acorn has its portfolio company - OmniMetrix™, Inc. The Company has an 80 percent equity stake in OmniMetrix.  Acorn Energy is a provider of high growth, wireless remote monitoring and control (IoT) services for critical industrial assets (generators, pipelines and other industrial assets). OTCQB-listed, the Company is headquartered in Wilmington, Delaware. 

Acorn Energy’s OmniMetrix™ remotely monitors emergency back-up power generation systems to increase their reliability. OmniMetrix™ is the leader and innovator in M2M wireless remote monitoring, control and diagnostics for pipelines and critical equipment.

OmniMetrix is a solution for making critical systems more reliable. The Company is a solution for pipelines and critical facilities internationally. This includes cell towers, medical facilities, data centers, public transportation systems, and federal, state, and municipal government facilities.

Acorn Energy has sold its DSIT Solutions interest. Acorn secured right of first negotiation to act as exclusive distributor for DSIT's new fiber-optic sensor technology for pipeline monitoring and control in the United States. Acorn Energy completed the sale of its remaining DSIT (Israel based) interest in February.

This technology offers a new range of high-value service opportunities, including monitoring for third party intervention or gas or oil leaks, to complement and expand Acorn Energy's existing OmniMetrix pipeline monitoring business, which currently provides cathodic or corrosion protection systems on gas pipelines to utilities and pipeline companies.

Recently, Acorn Energy announced results for its Q1 ended March 31, 2018.

Mr. Jan Loeb, Acorn Energy President and Chief Executive Officer, said, "We demonstrated solid operating progress in the first quarter with new orders increasing 12 percent and revenue rising 10 percent versus a year ago, in what is generally our seasonally slowest selling period. We were also successful in expanding our gross margin to 62 percent from 56 percent in the first quarter of 2017, generating a 21 percent increase in Gross Profit. Our OmniMetrix industrial monitoring and control subsidiary trimmed its operating loss to $55,000 in the first quarter from $196,000 in the first quarter of last year.”

Last month, Acorn Energy announced the hiring of Ms. Tracy Clifford, CPA as Chief Financial Officer (CFO) of the Company. Ms. Clifford succeeds former CFO Michael Barth, who served Acorn Energy through DSIT Solutions. Ms. Clifford formerly served as CFO, Principal Accounting Officer, Corporate Controller and Secretary for a publicly-traded pharmaceutical company and a publicly-traded REIT from 1999 to 2015.

Acorn Energy, Inc. (ACFN), closed Tuesday's trading session at $0.335, up 1.52%, on 38,715 volume with 15 trades. The average volume for the last 60 days is 35,617 and the stock's 52-week low/high is $0.149/$0.45.


The QualityStocks Company Corner

Auscrete Corp. (OTC: ASCK)

The QualityStocks Daily Newsletter would like to spotlight Auscrete Corp. (ASCK).

US-based Auscrete (OTC: ASCK), a building materials manufacturing company, this morning announced that it is finalizing plans to set up a production plant near London, ONT with a Canadian investment group. To view the full press release, visit:

Auscrete Corp. (OTC: ASCK) is a building products manufacturer of environmentally-friendly, energy-efficient housing and commercial structures using a lightweight hybrid concrete material developed through a proprietary technology. Auscrete’s unique process produces a medium that is cost-efficient, extremely soundproof, offers high insulation values, requires very low maintenance, won’t burn, non-toxic, highly resistant to insects and mold, and resists damage from hurricane forces and earth tremors. It’s a more affordable, energy-efficient “green” construction material that can be utilized for building residential housing and commercial structures.

Affordable homes are increasingly becoming more difficult to purchase in the U.S. with the median price of a new home consistently rising while wages stay stagnant in many areas and mortgage rates rise. The average price of new homes sold in the U.S. in 2017 was nearly $385,000, according to Statista. The homeownership rate in the U.S. has been in decline since 2004, the report states, and now amounts to a little more than 64 percent of Americans.

Auscrete’s lightweight concrete product is described as an aerated concrete material following infusion of a specially designed foaming agent during manufacture. This technology enables the product to have millions of minuscule air bubble “aggregates” introduced and evenly distributed throughout the cast sections, which creates a unique, lightweight product without compromising strength or structural integrity. Each hybrid panel also incorporates a distinctive XPS insulation amalgamation that guarantees greater comfort in a wide range of climatic conditions and a reduction in heating and cooling costs. The final product is a light and strong concrete panel with an extremely high insulation value, as well as excellent fire resistance and sound-proofing qualities.

Auscrete’s product also offers a high strength-to-weight ratio, allowing architects and engineers to develop new design and construction concepts that take advantage of the product’s reduced weight, which is nearly half that of normal concrete. Each panel can be cast in large sections, a common size being 16-feet by 8-feet, for easier transportation and faster construction on site. Savings are enhanced, not only by the energy efficiency of each panel, but through the use of mass production techniques. Auscrete estimates the company can produce a ready-to-move-in turnkey house for around $100 per square foot, which is significantly less than the 2017 median list price of $148 per square foot in the U.S., according to a report by Zillow.

Auscrete is constructing its flagship, 10-acre facility in Goldendale, Washington, on initially 5 acres the company recently purchased with the option to purchase another 5 adjacent acres. This new campus will ultimately comprise of 6 buildings, including 3 production buildings of 25,000 sq. ft. with each production buildings’ capacity of 100 homes annually, giving this flagship facility the ability to produce 300 homes or equivalent commercial structures per year.

During this construction phase, Auscrete has leased a commercial building in Goldendale. The facility will be used as a temporary headquarters and will also serve as a refurbishing station for production equipment the company has developed and used in its prior production plant. John Sprovieri, CEO and founder of Auscrete Corporation, is at the helm of the company with Mike Young serving as vice president of internal operations and Otto Paulette controlling the in-house mechanical services.

Auscrete’s Investor Relations Director, Lee Odom said, “The company’s construction process has already attracted interest from many developers, contractors and builders, some with large tracts of land looking to make available, significant numbers of Affordable Homes throughout the Country. Additionally, there have been significant commercial projects offered including 300 room destination hotel resorts, correctional facilities, a shopping complex, and a court house along with a flood of inquiries from people who are looking for more affordable building options”.

“This could really launch the commercial aspect for ASCK, apart from residential home production which so many investors are not yet aware of,” Odom said. “A strong combination of both will lead ASCK to better performance through all business cycles, thus continuing to enhance the shareholder values, which is always the ultimate goal of Auscrete Corporation.”

Auscrete Corp. (ASCK), closed the day's trading session at $0.0895, up 45.53%, on 67,750 volume with 6 trades. The average volume for the last 60 days is 123,332,584 and the stock's 52-week low/high is $0.0001/$0.10.

Recent News



The QualityStocks Daily Newsletter would like to spotlight GreenBox POS, LLC (GRBX).

Innovative hardware and software technology company GreenBox POS, LLC (OTCQB: GRBX) this morning announced that TrustGateway, a key component of the company’s QuickCard payment system, has demonstrated a high efficiency in preventing fraud on the GreenBox payment platform. To view the full press release, visit: Also today, NetworkNewsWire released a report on the company detailing how the company’s latest payment system, QuickCard, has been showing impressive market performance metrics ( Additionally, GRBX was recently the subject of an editorial titled “Meet GreenBox POS – A Blockchain Technology Company That Builds Customized Payment Solutions” by Tech Company News. To view the full press release, visit:

GreenBox POS, LLC (OTCQB: GRBX) is a hardware and software technology company that builds customized payment solutions in different industries. The company is headquartered in San Diego, California, with offices in Seattle, Wash.; Las Vegas, Nevada; and Vancouver, British Columbia, Canada. GreenBox, which has been awarded five provisional patents for its blockchain-based technology, delivers a fully integrated, intuitive, easy-to-use, point of sale (POS) system for a variety of businesses across a multitude of different market sectors.

GreenBox develops all software in-house and with international subsidiaries, which allows the company to provide individualized electronics modifications in partnership with different vendors. Custom POS machines are available as an upgrade from existing solutions currently in use. First-time merchants can also take advantage of custom-built kiosk machines powered by blockchain technology, complete with e-wallet integration downloadable via Android or iOS apps, or via installed cash-loading kiosks.

GreenBox develops POS (point of sale) software and hardware solutions; DEL (delivery app, APIs to POS and PAY); PAY (payment app, providing financial APIs to all other components); and KIOSK (deposit, cash and E-wallet management). The following flagship products, services and custom hardware are currently available:

  • QuickCard – the QuickCard kiosk handles all cash issues, both for cashless operations and for legacy cash; performs direct and immediate deposits from cash to blockchain and confirms bank account availability within minutes. Accepts cash, debit/credit cards, or ACH directly to most banks while settling funds instantly. All records are stored securely on blockchain. No faster deposit solution is available in the regular and non-traditional banking systems (unless depositing cash directly into a cash machine connected to a bank branch).
  • POS Solutions – GreenBox software, developed in-house and with international subsidiaries, features operational compliance, financial audit prep, expense tracking, tax payments, register-specific features, and data fidelity controls (backup/restore, cloud security, privacy, etc.). GreenBox POS software is fully integrated with Del and Pay Systems and features front register mode and back-end admin mode, in addition to in-admin mode to manage employees, vendors, expenses, taxes and compliance. All records are stored on blockchain with data reliably secured and protected.
  • LOOPZ – This delivery software solution offers service dispatcher back-end technology with manual and automatic modes. The software is uniquely designed to be effectively utilized for mobile delivery service operations with full autonomous dispatch capabilities. LOOPZ provides the following features: two mobile apps (driver and consumer) running on Android and IOS; direct reporting to point of sale inventory and use of pay for instant settlements; separate escrow setup for tips and merchant sale; all data and information is securely hosted on a blockchain platform.

The management team at GreenBox includes CEO Fredi Nisan, who comes from the POS and merchant services business sector. He recently completed a successful exit in the POS and ERP business, which he founded and managed through the exit. Joining Nisan is Ben Errez, executive vice president, who comes from the investment, consulting and big software and hardware industries. His previous executive roles include positions at Microsoft (including engineering management of Microsoft Office for complex scripts); IBM (with which he had an exit); and Intel. Errez has also consulted the world’s biggest private economy, World Trade Center, on payment systems, security, reliability and privacy of software and hardware development.

GreenBox POS, LLC (GRBX), closed the day's trading session at $0.65, up 25.00%, on 65,583 volume with 35 trades. The average volume for the last 60 days is 24,531 and the stock's 52-week low/high is $0.017/$0.8999.

Recent News


Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) (FRANKFURT: 6F6) (WKN: A2AKL8)

The QualityStocks Daily Newsletter would like to spotlight Victory Square Technologies Inc. (VSQTF).

Subject to all requisite regulatory approvals, Victory Square Technologies Inc. (CSE:VST) (OTC:VSQTF) (FWB:6F6) will acquire 15% percent of all issued and outstanding shares of Cloud Benefit Solutions Inc. (“CloudAdvisors”), an established and quickly growing Software-as-a-Service (SaaS) platform within the group life and health insurance industry, for $300,000 CAD in total consideration (the “Purchase Price”).

Victory Square Technologies Inc. (VSQTF) is a venture builder that creates, funds and empowers entrepreneurs working in the fields of blockchain technology, virtual reality, artificial intelligence, personalized health, gaming and film. As a technology incubator, Victory Square invests in game-changing entrepreneurs who are provided access to education programs, global mentorship networks, distribution partners, creative workspaces, resources, and other forms of operational support to help them scale internationally.

Victory Square has made multiple early partnerships and investments in the blockchain space. Approximately three years ago the company incubated and invested in BTL Group, which is now a $150 million dollar TSX-listed company offering blockchain solutions across multiple industries with particular focus on the finance, energy and gaming sectors. BTL’s showcase product – Interbit – is a blockchain platform that facilitates the rapid development of business applications that dramatically improve efficiency. Some of the world’s largest institutions are using Interbit to explore new opportunities on private blockchains.

A new social sports betting platform to be developed by Victory Square’s wholly owned subsidiary, FansUnite Media Inc. As a social sports data platform, FansUnite relies on robust data to allow members of its community to engage with like-minded individuals by collaborating, discussing, and predicting the winners of sporting events with a free virtual currency. The integration of blockchain technology into FansUnite’s social sports data platform could also lead to blockchain initiatives developed by other divisions and subsidiaries of Victory Square.

Integral to the FansUnite platform is the introduction of FAN Tokens, an in-game currency purchased with the cryptocurrency Ethereum that token holders can use to place wagers. FansUnite members will be able to earn FAN Tokens through participation in any number of networking effects identified in the company’s Bounty program.

“Blockchain technology and the inherent security it provides will enable us to push every envelope we can to build the most dynamic and responsive social sports betting platform,” said Darius Eghdami, Co-Founder and Chief Executive Officer of FansUnite. “The opportunity to secure data through Blockchain certainly appeals to the accountant in me and we are confident it will become the gold standard among sports betting sites around the world.”

Company subsidiary Victory Square Health Inc., which serves as the venture arm dedicated to companies focused on the development of solutions in personalized health technologies, has also invested in Personalized Biomarkers Inc. (PBI). PBI develops test kits that reliably predict the expected response to a number of therapies prior to prescription, with an initial focus on diabetes. Within this field, five potential biomarkers have been identified, allowing PBI to enter a $4 billion market opportunity.

“We are excited for the opportunity to partner with Personalized Biomarkers as they have correctly identified a massive market opportunity, and have formed an exceptional team of industry leaders,” said Shafin Diamond Tejani, Chief Executive Officer of Victory Square. “This is another investment that is fully aligned with our newly created subsidiary, and one we expect to significantly impact the landscape of personalized medicine.”

A partnership with Insight Diagnostics Inc., also through Victory Square Health, will focus on the development of a personalized diagnostic solution for the improved management and prevention of Type II diabetes.

The company’s investment in V2 Games, a development and publishing studio of high-quality mobile games, is another example of incubating great ideas. V2 Games is well known for its successful launch of PAC-MAN Bounce and Beast Brawlers, two of the company’s releases that are capturing the gaming world by the millions of downloads.

In a move designed to strengthen its presence in film and entertainment, Victory Square has acquired a 40 percent equity stake in United Film Fund II, LLC, which is producing three major motion pictures in 2017 and 2018 including “What They Had,” starring two-time Academy Award winner Hilary Swank.

“This kind of investment in entertainment and film represents a major plank for our Company going forward and we consider ourselves fortunate to have the opportunity to acquire this 40% stake in the Film Fund,” said Tejani, who has launched more than 40 startups in 21 countries that employ hundreds of people and generate more than $100 million in annual revenues. “We believe it’s another strong initiative in film production for us and our stakeholders,” he added.

Victory Square has strategically positioned itself in the legal cannabis industry through an investment in Tantalus Labs, a Canadian-based cannabis cultivation company. Tantalus Labs optimizes plant health and sustainable cultivation by using a unique, environmentally controlled greenhouse engineered specifically for growing cannabis. Called a “SunLab,” the greenhouse takes 90 percent less electricity, uses filtered rainwater, and cools the growing environment to prevent stagnant moisture, recycling the air every 7 minutes to achieve maximum airflow.

Victory Square and its leadership team have seamlessly transitioned from its former identity as Fantasy 6 Sports Inc, a company focused solely on fantasy sports, mobile gaming and immersive sports, to a strategic technology company that creates, funds and successfully executes leading-edge ideas. A long-time technology entrepreneur and advocate of the industry, Tejani received the Person-of-the-Year Award at the 2017 Technology Impact Awards in British Columbia, a hallmark award category that recognizes betterment of the tech industry through leadership and philanthropic or enterprise skills and talents. Tejani has pledged to match up to $1 million in donated funds to be shared by a number of Canadian endeavors aimed at education and child-safe projects.

“These are exciting and important steps in the evolution and growth of our Company, and which properly and fully align with our strategic plan focusing on our core competencies in Blockchain Technology, Artificial Intelligence, Gaming, Personalized Health, Film and Virtual, Augmented and Mixed Reality,” said Tejani. “We’re spurred on by the success we have had in building on our original forays into fantasy sports, mobile gaming and immersive sports. In addition, we are energized by our most recent initiatives in sports, personalized health and entertainment and the confidence being shown by our shareholders in the dynamic direction of the Company.”

Victory Square Technologies and its management team believe innovation, incubation of excellent ideas and social responsibility are at the core of its growing success.

Victory Square Technologies Inc. (VSQTF), closed the day's trading session at $0.64, up 11.50%, on 24,455 volume with 16 trades. The average volume for the last 60 days is 25,752 and the stock's 52-week low/high is $0.298/$3.32.

Recent News


Earth Science Tech, Inc. (OTC: ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech, Inc. (OTC: ETST) has revamped its line of CBD products and will extend its line of raw dark chocolates in conjunction with joint venture partner Karmavore Superfoods. Research shows that, in several states where marijuana is legalized, such as Colorado, Oregon and Maine, both edibles and chocolates are growing.

Earth Science Tech, Inc. (OTC: ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $0.76, up 4.11%, on 5,104 volume with 15 trades. The average volume for the last 60 days is 11,475 and the stock's 52-week low/high is $0.324/$1.62.

Recent News


Zenosense, Inc. (OTCQB: ZENO)

The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO).

Health care technology company Zenosense, Inc. (OTCQB: ZENO) has completed two important milestones recently. The first was a successful second round of quantitative testing for the MIDS detection technology; the technology is core to the development of MIDS Cardiac™, a handheld device to rapidly test for certain cardiac biomarkers at the point of care.

Zenosense, Inc. (OTCQB: ZENO) (the “Company”) is a healthcare technology developer that participates in transformational, disruptive medical diagnostic projects; particularly handheld devices used at the Point of Care which are displacing slow and expensive laboratory tests.

Zenosense is primarily focused on the development and commercialization of MIDS Cardiac™ through the Company’s joint venture ownership in MIDS Medical Limited (“MML”). MIDS Cardiac is in development as a cost-effective, handheld Point of Care (“POC”) diagnostic device and disposable test strip for the early, rapid detection of suspected acute myocardial infarction (“AMI”, or “heart attack”).

Identification of very low levels of cardiac markers can significantly accelerate critical triage, diagnosis, treatment and disposition of patients reporting chest pain. Cardiac troponin is well documented as the preferred biomarker for diagnosis of AMI, with evidence continuing to demonstrate that high sensitivity troponin is the most powerful prognostic biomarker for the assessment of cardiovascular risk in the general population. However, highly sensitive troponin assays are currently available only on state of the art, central laboratory analyzers. These analyzers are extremely expensive, not generally available at the POC and slow to turnaround results (typically 60 minutes) when time is critical.

True, high-sensitivity devices are not available in smaller handheld devices at the POC, where they are most needed. This is because the optical detection systems generally used in central laboratory analyzers cannot be effectively miniaturized.

MIDS Cardiac uses the patented MIDS technology platform, exclusively available to MML. Instead of using conventional optical detection, MIDS can detect and quantify assay beads nano-magnetically. This means it can be incorporated in a small device expected to achieve highly sensitive detection levels, which can support true high sensitivity cardiac biomarker tests in emergency settings, at the POC.

Harnessing world-class expertise, the MML laboratory is located at the prestigious Sci-Tech Daresbury campus in the U.K., internationally recognized for leading-edge, scientific research and commercial development. MML has the sole rights to the MIDS technology platform, which is protected by patent applications already granted in China and the USA, and applications now in the national phase in all other key geographic areas.

MIDS Cardiac aims to provide a single troponin I or T test within 3 minutes and three panel assay (additional cardiac biomarkers) on a disposable test strip within 8 minutes, using a hand-held device costing a fraction of the price of laboratory analyzers.

MIDS Cardiac should only require a pin prick of blood for a single assay test carried out on an easy-to-use, disposable microfluidic test strip. MIDS Cardiac is being designed to be operated quickly by minimally trained personnel, producing a simple to interpret result in emergency settings, even in the back of an ambulance.

Initial testing of the electronic and microfluidic components of the MIDS Cardiac “Hybrid Strip” system was completed in November 2017. The Hybrid Strip system used for development testing aims to replicate as closely as possible a fully integrated Lab on Chip MIDS test strip set-up. Development testing was conducted on both the assembled hybrid unit and its electronic and microfluidic components separately, focusing mainly on the electronics of the magnetic sensing system.

Testing revealed that a variety of brands and sizes of commercially available assay beads could be magnetically detected in very low quantities, including samples of beads that were previously undetectable. In several instances, the current “limit of detection” appeared to already be at or near to the range advised by MML’s assay consultants as suitable for a high sensitivity troponin assay.

Dr. Nasser Djennati, MML’s Managing Director and Chief Scientific Officer, said; “These results come in at the very high end of detection expectations, even at this Hybrid Strip stage. As we move forward into true Lab on Chip construction, I expect detection levels to improve further still.”

Cardiovascular disease is the leading cause of death in the western world, accounting for more than 17 million deaths in Europe and the United States alone. Nearly 20 million patients each year visit an emergency room with reports of chest pain, with hundreds of millions spent on unnecessary admissions to the hospital. Zenosense Inc. is confident MIDS Cardiac will deliver unparalleled levels of accuracy, speed, reliability, ease of use and cost savings, making it the future device of choice for hospitals, emergency rooms, medical practitioners, paramedics and in low-resource settings.

The MIDS technology is also seen as having a far wider application, with the platform being capable of performing Point of Care immunoassay tests for a vast array of common healthcare concerns, a market projected to be worth $23.7 billion per year worldwide by 2019. The medical testing market as a whole is projected to be worth $53.34 billion by 2021. Zenosense believes the MIDS technology could be the most significant advance in diagnostic testing services in decades.

Zenosense, Inc. (ZENO), closed the day's trading session at $0.43, up 7.18%, on 117,272 volume with 38 trades. The average volume for the last 60 days is 273,070 and the stock's 52-week low/high is $0.15/$0.895.

Recent News


DPW Holdings, Inc. (NYSE American: DPW)

The QualityStocks Daily Newsletter would like to spotlight DPW Holdings, Inc. (DPW).

DPW Holdings, Inc. (NYSE American: DPW), a diversified holding company, announced Microphase Corporation, a division of DPW subsidiary Coolisys Technologies, Inc., won a $2.1 million contract award from a first-tier U.S. government defense contractor to supply its sophisticated communications filters to be used in combat warfare system components.

DPW Holdings, Inc. (NYSE American: DPW), is a diverse holding company pursuing a growth strategy of  acquiring undervalued assets with disruptive technologies with a global impact.

The company invests in diverse industries within the commercial, defense/aerospace, industrial, communication, medical, crypto-mining, hospitality, textile, and corporate investment/lending sectors. DPW has evolved and grown from being a leader in advanced power products. Through its subsidiaries, the company continues to be a leader and supplier of innovative technologies, advanced design and development services, and state-of-the-art power products and solutions.

Through its wholly owned Coolisys Technologies, Inc. subsidiary, DPW is committed to offering world-class technology-based solutions for critical applications and lifesaving services that are primarily driven by innovation. Coolisys targets to the defense, aerospace, naval, homeland security, medical, telecom, datacom and industrial markets. Its growth strategy centers on core markets that are characterized by “high barriers to entry” and require specialized products and services not likely to be commoditized. Through a portfolio of companies, Coolisys is engaged in developing and manufacturing advanced switching power products and power solutions that utilize a customized digital power management and resonant topology to attain:

  • The highest efficiency and highest density power converters and inverters
  • Specialized complex airborne high-frequency, radio frequency (RF), and microwave detector-log video amplifiers (DLVA)
  • Very high-frequency filters
  • Naval power conversion and distribution equipment

Coolisys offers its technology and services through three primary groups: the Power Solutions Group (PSG), the Defense and Aerospace Solutions Group (DSG), and the Advanced Service Industries (ASI) Group. Coolisys manages five divisions:

  • Digital Power Corporation, a leader in providing power electronics technology that is based in northern California.
  • Digital Power Limited dba Gresham Power Ltd, a designer and manufacturer of power distribution systems primarily for Naval use that is based in Salisbury, UK.
  • Microphase Corporation, a designer and manufacturer of microwave electronics technology that is based in Shelton, Connecticut.
  • Power-Plus Technical Distributors, a value-added distributor that is based in Sonora, California.
  • Enertec Systems, a developer and manufacturer of specialized advanced electronic systems for the defense and aerospace sectors that is based in Karmiel, Israel.

DPW’s portfolio of wholly owned subsidiaries also includes Digital Power Lending, LLC (DPL), a California private lending company operating under Financial Lender’s License ##60DBO-77905. DPL is dedicated to strategically providing capital to small and middle-size businesses for an equity interest in addition to loan fees and interest. DPL provides secured and unsecured debt financing for public and private companies. These loans will typically have a six to 12-month maturity and range from $250,000-$5 million. DPL is active in bridge loans, receivable financing, inter company loans and micro loans. DPL will work with a network of company owned ATMs (terminals) in California, which will help utilize its CA Finance Lending License and enable the company to offer micro loans of up to $500 or less.

Management has over 50 years of Wall Street experience of investing in, and building companies. DPL’s desire is to bring world-class companies lending opportunities while allowing main street investors to participate. Deal flow and organization comes from an extensive network of investment bankers, business brokers, family offices, and institutional clients enabling DPL to engage and fund the most compelling companies from Silicon Valley to Wall Street.

To date, DPL has funded over $19 million in loans. Since inception, DPL has internally funded over $15 million to DPW’s portfolio companies and wholly owned subsidiaries. As for companies outside DPW, DPL has lent over $4 million in commercial and real estate loans. DPL has funded INVO Bioscience, Medovex, Parallax, Alzamend Neuro, as well as hospitality clients, such as Guilia DTLA and Prep Kitchens.

Another subsidiary wholly owned by DPW is Super Crypto Mining, Inc., a cloud computing service that provides shared and managed computing resources optimized for various block chain mining solutions. Based in Newport Beach, California, Super Crypto Mining leverages its engineering expertise and existing locations to create cryptocurrency mining facilities throughout the world. The company owns and maintains the computing resources and sells access to their use. The established mining is on the Top 3 crypto-currencies with the goal of having 10,000 miners deployed in 2018. Super Crypto Mining endeavors to leverage its engineering expertise and existing global facilities (high-security defense business locations) to secure mining farms. Super Crypto Mining is a rapidly growing organization that recently strategically secured 25 mega watts to power the company’s mining farm. For crypto currency mining, locations with inexpensive power and secure capacity are minimal and hence costly. Having such a location allows the company to grow its mining business to more than 20,000 mining machines. Super Crypto Mining continues to purchase mining machines and explore opportunities to expand its services into other related areas including mining farm real estate investments, mining machine development, and mainstream blockchain projects.

DPW additionally has beneficiary ownership in MTIX International, Inc., the parent company of MTIX, Ltd. and I.AM, Inc.

MTIX was acquired by Avalanche International aka MTIX International, Inc., in August 2017 and offers “green technology” that uses a proprietary laser process to enhance the surface of textiles. This process reduces water usage by approximately 75 percent, reduces greenhouse gases by approximately 90 percent, and reduces chemical use by approximately 95 percent.

I.AM, acquired in May 2018, owns and operates hospitality offerings that include four Prep Kitchen brand restaurants and Giulia DTLA.

Utilizing a shareholder-centric approach to compensation, DPW has formulated the following 10-year objectives:

  • Achieve compounded annual revenue growth of 25-35%
  • Achieve compounded annual net Income growth of 5%
  • Achieve positive unrestricted free cash flow by the end of 2019

DPW is led by a seasoned team of successful business professionals and entrepreneurs. The company is headquartered in Newport Beach, California.

DPW Holdings, Inc. (DPW), closed the day's trading session at $0.5445, off by 1.07%, on 8,087,361 volume with 8,448 trades. The average volume for the last 60 days is 2,002,402 and the stock's 52-week low/high is $0.4911/$5.95.

Recent News


PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)

The QualityStocks Daily Newsletter would like to spotlight PreveCeutical Medical Inc. (PRVCF).

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that, in keeping with the Company's vision of becoming a global preventive healthcare company, PreveCeutical has launched a medicinal cannabis division (the "Cannabis Division").

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word “PreveCeutical” – a combination of the words “preventive” and “pharmaceutical” – was a precursor to the company’s formation and incorporation in October 2015.

The company’s first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical’s research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical’s science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.’s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company’s core.

PreveCeutical Medical Inc. (PRVCF), closed the day's trading session at $0.03, off by 8.81%, on 665,312 volume with 109 trades. The average volume for the last 60 days is 514,429 and the stock's 52-week low/high is $0.002/$0.20.

Recent News


Marifil Mines Ltd. (TSX.V: MFM) (OTCQB: MFMLF)

The QualityStocks Daily Newsletter would like to spotlight Marifil Mines Ltd. (MFMLF).

The world has reached “peak gold,” with reserves being mined much faster than they are being replaced  by new discoveries, and with virtually no new major gold deposits being identified, according to gold and mining experts quoted by Sovereign Man ( Aiming to help meet the growing demand for gold, Marifil Mines Ltd. (TSX.V: MFM) (OTCQB: MFMLF) recently completed a drilling program at a flagship property in Argentina where it searches for gold and zinc.

Marifil Mines Ltd. (TSX.V: MFM) (OTCQB: MFMLF), headquartered in Vancouver, Canada, is engaged in the exploration, evaluation and acquisition of mineral rich resource properties in Argentina. A rising global demand for cobalt and lithium is generating interest in Marifil Mines and its resources located within South America’s famed “Lithium Triangle,” which include 15,267 hectares spanning its recently acquired Ratones and Fraile claims, as well as two lithium properties covering the southern portions of the Carachi Pampa salar in the Argentine province of Catamarca.

The company’s property also includes the Las Aguilas nickel-copper-cobalt deposit property, with more than four contiguous claims in the San Luis province of Argentina. The Las Aguilas property, which is 100% owned by Marifil, is noted as one of the largest cobalt properties in Argentina. Other noteworthy properties in the company’s portfolio include the Toruel copper-silver property, with more than two contiguous claims, and additional potash properties in Punta Colorada, Pedernal and El Carmen.

Marifil’s sizable portfolio of cobalt and lithium claims in what is recognized as the world’s most prolific mining jurisdiction for these resources strategically positions the company to benefit as global initiatives push demand for lithium-ion batteries toward a frenzy. Zion Market Research, a leading research and consulting firm, has forecast that the lithium-ion battery market could hit $67 billion by 2022, realizing a CAGR of more than 13.7% from 2017-2022. Both lithium and cobalt are major components of these energy storage solutions, with industry data indicating that the battery industry currently consumes roughly 42 percent of global cobalt production.

The company is reviving a lithium exploration program that was active in Argentina a decade ago, building on an unexplored mine it owns there. Marifil will utilize a large proprietary geologic and geochemical data base it developed during its 2009 lithium exploration program in the Salta and Catamarca province sites to resume lithium exploration in the region.

Applications for a second mine and negotiations to purchase a third property are underway, which would establish a significant property portfolio of ‘salar’ brine evaporation lakes. Hydrothermal solutions emanating from regional faults in area volcanoes often enrich the brine with lithium, boron, potassium and magnesium.

In addition to nearly 152,000 acres of lithium-staked properties, Marifil owns 887 acres of land for cobalt exploration and 91,565 acres of gold mining rights in an advanced exploration stage in San Roque that company engineers indicate has high gold discovery potential with “excellent infrastructure and mining friendly politics.”

To date, more than $7.5 million has been invested assessing Marifil’s flagship San Roque gold property, including nearly 16,000 meters of diamond core drilling. The property is jointly owned by Marifil and Novagold Resources, with Marifil holding a 51% stake and serving as the current project operator. The company recently commenced a drilling campaign to further evaluate several deposits of significant gold-silver-indium-lead-zinc mineralization on a 4-kilometer-long zone.

Marifil has closed a private placement funding for $2 million that will inject additional life into the company. Proceeds from the funding will benefit acquisition plans, the ongoing drilling program at Marifil’s gold claim and other output from its general working capital accounts.

Robert Abenante, a chartered professional account, serves as president and chief executive officer of the company. He has extensive experience in the public markets and has served as an officer and director of several public and private companies across various industries, with particular success in the mining sector.

Marifil Mines Ltd. (MFMLF), closed the day's trading session at $0.096, even for the day. The average volume for the last 60 days is 2,001 and the stock's 52-week low/high is $0.01/$0.165.

Recent News



The QualityStocks Daily Newsletter would like to spotlight FANDOM SPORTS Media Corp. (FDMSF).

FANDOM SPORTS Media (CSE:FDM) (OTC:FDMSF) (FRANKFURT:TQ42) (“FANDOM SPORTS” or the “Company”) has increased its ability to communicate with global investors by opening a dedicated IR manager position. Mr. Eric Bau is familiar with the North American investment community and is excited to reconnect with the community on behalf of FANDOM SPORTS.

FANDOM SPORTS Media Corp. (CSE: FDM) (OTC: FDMSF) (FRA: TQ42) taps into the primal, unfiltered passion of sports fans from around the world by providing an uncensored social media platform delivered through the FANDOM SPORTS mobile app. As an aggregator, curator and instigator of both company-created and user-generated content, the FANDOM SPORTS app is designed to entertain sports enthusiasts with real-time, interactive content on a mobile only app that offers bragging rights and real-life rewards. True sports addicts will appreciate an app that allows fans to pick a fight or create their own FanFights and rule over others as they trash talk their way to victory. The FANDOM SPORTS proprietary data centric “argument engine” measures and scores opinionated dialogue, as well as establishes consensus, giving fans and users the ability to dive deeper into one-of-a-kind cultural moments, cheer on favorite sports teams and slam dunk some sweet rewards.

Building on the company’s tag line – “Pick a Fight” – the FANDOM SPORTS app provides an always fresh, authentic rush of deeper-than-surface interactive content that resonates with the targeted age demographic of 18-34. Intense sports fans aren’t afraid of stepping up to the plate to engage other users by unleashing their opinions within the app’s structured debate resolution tool coined “FanFights.” Sports-loving fans can explore, gloat, vote, invite friends, create provocative FanFight topics and play to win while inside the FANDOM SPORTS app, which is currently available in the Apple App store and coming to the Google Play store imminently. The company’s self-learning algorithm predicts and collects user preferences while building relevant personalized FanFight channels, bringing the concept of competitive, in-your-face conversation to a whole new level of sports entertainment.

The FANDOM SPORTS app is free to play (F2P) with in-app purchase and subscription capabilities. The gaming aspect of the ecosystem is built on behavioral economics and delivers multiple revenue streams by maximizing average revenue per daily active user (ARPDAU) and user-generated content (UGC), with select placement of high-impact video and moment-based marketing as part of the brand-sponsored FanFights and in-app offers. The global platform enables applications (either FANDOM SPORTS created or 3rd party apps) to be operated in partnership with leading sports themed brands, leagues, and service providing companies within three verticals – live action, eSports, & fantasy – from around the world by supplying “interactive sports entertainment” to fans. The FANDOM SPORTS platform creates a bullet-proof snapshot of the app’s fan base through a Blockchain supported “PlayerCard” in tandem with the “Engagement Score”, which doubles as an invaluable acquisition and retention tool for its business operators. FANDOM SPORTS hosted transactions are placed on the distributed ledger, making them immutable and public to verified users interacting within the business ecosystem. Tracking this digital footprint provides extremely valuable metadata generated by users’ very dynamic behavior and sports passion.

FANDOM SPORTS’ Brand and Sponsorship partners are harnessing the affluent sports fans age 18-34 with integrated marketing content and service experience. The moments-based marketing integration will translate through FanCoin redemption, in exchange for items provided by programs established by FANDOM SPORTS and its clients. These programs are a key part of the business model and covers, as an example, the following partners; Sports Leagues, TelCo’s service offerings, and Content owners (i.e. FANDOM SPORTS provides new paying customers to the owners of pay-per-view platforms).

“Pick A Fight. Talk Trash. Get Rewarded.”

FANDOM SPORTS Media is an entertainment company that aggregates, curates and produces unique fan-focused content.

The FANDOM SPORTS App is the Company’s core product, which is the ultimate destination for unfiltered raw sports talk. The app allows passionate sports fans to unleash their primal sports passions, pick fights and earn rewards.

So download the app and bring your crew. Talking trash is better with friends. The more you invite, the more FanCoins you earn.

You may also visit the Company’s website at or contact them directly at


The CSE has not reviewed and does not accept responsibility for the adequacy and accuracy of this information. This news release may contain forward-looking statements. These forward-looking statements do not guarantee future events or performance and should not be relied upon. Actual outcomes may differ materially due to any number of factors and uncertainties, many of which are beyond the Company’s control. Some of these risks and uncertainties may be described in the Company’s corporate filings (posted at

The Company has no intention or obligation to update or revise any forward-looking statements due to new information or events

FANDOM SPORTS Media Corp. (FDMSF), closed the day's trading session at $0.079, up 13.18%, on 25,258 volume with 2 trades. The average volume for the last 60 days is 9,848 and the stock's 52-week low/high is $0.0601/$0.2864.

Recent News


Marijuana Company of America Inc. (OTC: MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Based in Escondido, California, Marijuana Company of America, Inc. (OTC: MCOA) focuses on providing turn-key services to the legal cannabis and industrial hemp industries. The company provides varied services and products via its strategic cross-country platform. Fundamentally, MCOA is undergoing development to support an array of portfolio companies that participate within these sectors.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.0305, even for the day, on 7,576,390 volume with 247 trades. The average volume for the last 60 days is 7,814,880 and the stock's 52-week low/high is $0.022/$0.0728.

Recent News


Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

At Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) 2018 Annual General Meeting, all motions were passed. The company is proceeding on schedule with its reorganization into four new wholly owned subsidiaries to serve the nicotine, hemp, pharmaceutical and cannabis industries. Also today, NetworkNewsWire released a report on the company detailing how LXRP’s lipophilic enhancement technology DehydraTECH™ is changing how cannabinoids are poorly absorbed by the body’s gastrointestinal tract. Previously, consumers have turned to cannabis smoking to achieve higher effectiveness.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria’s products and others on the market is the company’s disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the “unusual” taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria’s processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company’s patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria’s lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world’s most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $1.65, off by 2.94%, on 85,501 volume with 140 trades. The average volume for the last 60 days is 243,041 and the stock's 52-week low/high is $0.30/$2.54.

Recent News


QMC Quantum Minerals Corp. (TSX-V: QMC) (FSE: 3LQ) (OTC: QMCQF)

The QualityStocks Daily Newsletter would like to spotlight QMC Quantum Minerals Corp. (QMCQF).

QMC Quantum Minerals Corp., (TSX.v:QMC) (FSE:3LQ) (OTC PINK:QMCQF) (“QMC” or "the Company").  QMC is pleased to provide an update on the company’s 100% owned Irgon Mine Project located within the prolific Cat Lake-Winnipeg River rare-element pegmatite field of S.E. Manitoba, which also hosts Cabot Corporation’s nearby Tantalum Mining Corporation of Canada (“TANCO”) rare-element pegmatite. Also today, NetworkNewsWire released a report on the lithium industry highlighting QMC Quantum Minerals Corp. (TSX-V:QMC) (OTC:QMCQF).

QMC Quantum Minerals Corp. (TSX-V: QMC) (FSE: 3LQ) (OTC: QMCQF) is a British Columbia based company engaged in the business of acquisition, exploration and development of natural resource properties. QMC’s focus is on creating shareholder value through strategic acquisition and development of high quality lithium, silver, gold, nickel, copper and zinc prospects.

QMC’s current properties are in the Canadian province of Manitoba, one of Canada’s most productive, centrally located mining regions. These resources include the Irgon Lithium Mine project and two Volcanic Massive Sulphide (“VMS”) properties – the Rocky Lake and Rocky-Namew known collectively as the Namew Lake District Project – which contain base metal-rich mineral deposits. Excellent access and well-developed mining infrastructure to the company’s wholly-owned Irgon Lithium Mine Project offers significant value and ramps up the near-term production schedule, putting QMC in a position to take advantage of rising lithium prices.

The region’s historic resource estimate of lithium is well documented in a 1956 Assessment Report developed by a previous owner, Lithium Corporation of Canada Ltd. The project’s historical resource estimate of 1.2 million tons grading 1.51% lithium-oxide over a strike length of 365 meters and to a depth of 213 meters is being updated by QMC through a detailed channel sampling and subsequent drill program.

North Face Software Ltd. recently created an interactive 3-D model of the Irgon Dike utilizing all historical data derived from past drilling and underground work. The 3-D model clearly demonstrates that exploration and underground development has only taken place on the central portion of the dike, leaving significant potential to quickly increase tonnage.

The company’s latest assay results, obtained from 144 channel samples at QMC’s Irgon Lithium Mine Project, provided encouraging and positive results that compare favorably with the historic assays. QMC has received a drill permit from the Sustainable Development Office of the Manitoba government and is in the process of requesting and assessing bids from drilling contractors. The company plans to begin a 2,000-meter drill program to confirm the historic lithium oxide assay results documented in the historic 1953-54 drill program.

QMC’s experienced leadership team includes specialists in mineral exploration, geology, engineering, new business development, marketing and investor relations. The company’s team of qualified advisors includes consultant Bruce E. Goad, P.Geo., who has 40 years of experience in mineral exploration in Canada, Argentina, Asia and Africa. As a Qualified Person, Goad has worked on numerous deposit styles including rare element pegmatites, porphyry, banded iron formation (BIF) gold deposits, skarn, greisens,  and VMS. He has a wide and varied skill set which includes precious, base, industrial and rare metal projects with a sharp focus on gold exploration. Goad is the author of several scholarly publications on pegmatite granites of the southeastern Manitoba region.

The market for lithium has surged over the past three years with prices per metric ton tripling. The world’s rising demand for portable power can easily been seen in the electric vehicle and mobile device industries – both of which use lithium-based, renewable batteries as a power resource. QMC’s high potential prospects and experienced management team, both in geology and corporate finance, put QMC and its shareholders in an excellent position to take advantage of the lithium, precious and base metals markets.

QMC Quantum Minerals Corp. (QMCQF), closed the day's trading session at $0.2679, off by 0.78%, on 33,620 volume with 15 trades. The average volume for the last 60 days is 115,109 and the stock's 52-week low/high is $0.078/$1.46.

Recent News


Petroteq Energy Inc. (TSX.V: PQE) (OTC: PQEFF)

The QualityStocks Daily Newsletter would like to spotlight Petroteq Energy Inc. (PQEFF).

Petroteq Energy Inc. (TSXV: PQE) (OTC: PQEFF) (FSE: PQCF) ("Petroteq" or the "Company"), a company focused on the development and implementation of proprietary technologies for the energy industry, is pleased to announce that it has signed a Letter of Intent to pursue additional acreage and resources in Utah. 

Petroteq Energy Inc. (TSX.V: PQE) (OTC: PQEFF) is a Canadian-registered, publicly traded company engaged in the development and implementation of proprietary technologies for the environmentally safe extraction of heavy oils from oil sands, oil shale deposits and shallow oil deposits. The company is focused on oil and gas exploration and production on mineral leases it owns in Texas with Accord GR Energy Inc. and in expanding production capacity at its Asphalt Ridge heavy oil extraction facility in Utah.

Petroteq Energy is also participating in a blockchain initiative aimed at solving the global transaction needs of the oil and gas industry through the development of PetroBLOQ, the Company’s collaboration formed with First Bitcoin Capital Corp. (OTC: BITCF). PetroBLOQ’s novel blockchain-based oil and gas supply chain management platform is currently being co-developed by the two companies.

PetroBLOQ recently joined the Enterprise Ethereum Alliance (“EEA”), the world’s largest open-source blockchain initiative. Membership with the 200-member EEA represents a wide variety of industries and offers 14 industry-focused, member-driven working groups.

“Joining this community of forward-looking enterprises and blockchain innovators is an important step for PetroBLOQ as we develop transformative solutions for the oil and gas industry,” said Petroteq Energy CEO Alex Blyumkin.

In addition, Petroteq has joined the American Petroleum Institute (API). The API is the only national trade association representing all facets of the oil and natural gas industry, promoting safety across the industry globally and influencing public policy in support of a strong, viable oil and natural gas industry. “API has led the development of operating standards for our industry, and we look forward to contributing our experience with oilfield technologies in addition to introducing our PetroBLOQ platform to its members throughout the supply chain,” Blyumkin previously stated.

Petroteq Energy’s patent-pending application is a closed-loop, solvent-based process, which results in significantly lower per-barrel production costs than those incurred with traditional hot water-based oil sands extraction technologies. This green technology utilizes a small, modular footprint, produces no greenhouse gases, requires no high temperatures, leaves only clean dry sand, and could be deployed to unlock heavy oil deposits located around the world.

The Company’s Asphalt Ridge mineral lease on 3,000-plus acres in northeastern Utah features a large contingent oil sands resource base with an estimated 87 million barrels of oil equivalent. In 2015, the company produced 10,000 barrels of oil from the Utah location and plans to increase production are underway. Utah holds over 32 billion barrels of undeveloped oil sands resources, which are also known as “oil-wet” deposits containing a mixture of sand and a dense, extremely viscous form of petroleum referred to as bitumen or tar. A recent upswing in developing domestic energy sources has intensified interest in technological advances such as Petroteq’s Liquid Extraction System.

The company’s Texas location includes an ownership interest (46%) in 7,000 acres under mineral leases with Accord, a Houston-based oil and gas exploration company that focuses on the development and recovery of heavy oil reserves and deposits. Two enhanced, licensed oil recovery technologies designed to increase oil recovery from more than 80 shallow oil wells on the property are expected to substantially improve the recovery rates of heavy oil deposits in this area. In both the Utah oil sands and traditional oil patch Texas project, the Company, its subsidiaries and Accord are using proprietary technologies, processes and methodologies to recover heavy oil, providing a distinct, strategic economic advantage for Petroteq Energy and its shareholders.

The Company continues to evaluate the development of other medium to heavy oil exploration, production and recovery projects on a global basis through a variety of structured agreements. These opportunities or other arrangements with private and governmental entities that utilize Petroteq Energy’s proprietary licensed technologies are expected to generate a significant return on investment.

The Company’s management team, board of directors and officers form an invaluable cross-section of industry leaders with extensive experience ranging from chemical engineering and solvent research, business development, international project management, entrepreneurial achievements, and senior management for global energy companies in North America and the Middle East. This impressive knowledge base covers both conventional and unconventional oil and gas projects and production, both in upstream and downstream industry sectors.

Petroteq Energy Inc. (PQEFF), closed the day's trading session at $0.94, off by 1.83%, on 349,493 volume with 261 trades. The average volume for the last 60 days is 198,348 and the stock's 52-week low/high is $0.28/$1.8892.

Recent News


The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.